This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Putney Launches First FDA Approved Veterinary Generic Of Simplicef®

PORTLAND, Maine, Feb. 11, 2013 /PRNewswire/ -- Putney, Inc., a rapidly growing pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has launched generic veterinary Cefpodoxime Proxetil tablets. Putney's veterinary Cefpodoxime Proxetil is the first and only generic approved by the FDA's Center for Veterinary Medicine (CVM) as equivalent to Simplicef®. Putney's generic Cefpodoxime Proxetil is FDA CVM approved to treat certain skin infections in dogs.

Jean Hoffman, president and CEO of Putney, expects Putney's veterinary Cefpodoxime Proxetil to rapidly penetrate and expand the $25 million market, as veterinarians who currently prescribe either the brand or a human-approved generic choose Putney's pet-approved generic product. "Pet owners are looking for more affordable, equivalent medications to treat their pet family members, just like the FDA approved generic drugs that they are comfortable using when doctors prescribe medication for their human family," says Hoffman. According to a study by IMS Health, generics now account for over 80% of human prescriptions filled in the United States resulting in a savings of $3 billion every week for American consumers. 1 By contrast, generics in the veterinary pharmaceutical industry are just taking off -- only 7% of FDA CVM-approved medicines for dogs and cats have a veterinary generic equivalent. 2

Putney developed its Cefpodoxime Proxetil tablets in convenient once-a-day 100mg and 200mg doses, just like the brand.  "We expect pet owners and veterinarians to opt for Putney's Cefpodoxime Proxetil because it's FDA approved for dogs, it's convenient, and it's more affordable," says TJ Dupree, Putney's chief operating officer. Putney's Cefpodoxime Proxetil tablets will cost at least 25% less to veterinarians than the branded product.

With the addition of this product, Putney now has three FDA approved veterinary generic medicines on the market, and Hoffman notes that Putney's Product Development and Regulatory team is currently overseeing more than twenty more products in various phases of development and FDA review. "We believe we have the deepest pipeline in veterinary medicine, aimed at providing veterinarians and pet owners with FDA approved generics of pet medicines where price is a barrier to prescribing and using the right drug for each pet's medical need. The approval of Putney's bio-equivalent Cefpodoxime Proxetil is just the beginning," says Hoffman.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs